Download PDF
Thromb Haemost 1985; 53(02): 245-248
DOI: 10.1055/s-0038-1661285
Original Article
Schattauer GmbH Stuttgart

Urokinase Quality: Analysis of Different Preparations

W Rogatti
1   The Research and Development, Schwarz Co. Ltd., Monheim, West Germany
,
K Yokoigawa
2   The Research Department of Biological Chemistry, Wakamoto Pharmaceutical Co. Ltd., Tokyo, Japan
,
T Kobayashi
2   The Research Department of Biological Chemistry, Wakamoto Pharmaceutical Co. Ltd., Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Received 28 December 1984

Accepted 02 February 1985

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Five commercially available German Urokinase (UK) preparations were examined for purity, fibrinolytic activity, and molecular weight composition. With the exception of one preparation (B) all samples showed comparable fibrinolytic activity (91-107% of the activity declared). Preparations A, D, and E contained almost exclusively high-molecular-weight UK (HMW-UK), i.e., 82-86%. However, preparation C (from kidney tissue cultures) contained 95% of low-molecular-weight-UK (LMW-UK), and sample B consisted of nearly equal amounts of both HMW-UK and LMW-UK (47:53). Purity criteria (coagulative and lysozyme activity, endotoxin content, protease activity, HBS antigen) were fulfilled by preparation E, and, with certain restrictions, also by preparations A and C.

Keywords

Urokinase preparations - Quality control - High and low molecular weight urokinase - Fibrinolytic activity
 

  • References

  • 1 Tilsner V. Klinische Erfahrungen bei der Urokinase-Behandlung. Arzneim-Forsch/Drug Res 1984; 34: 55-61
    PubMedGoogle Scholar
  • 2 Zimmermann R, Harenberg J, Mörl H. Tiefe Venenthrombosen: Neuere Aspekte der medikamentösen Behandlung. Dtsch Ärzteblatt 1983; 80: 31-40
    PubMedGoogle Scholar
  • 3 Lüdtke-Handjery A. Die Behandlung der tiefen Becken-Beinvenenthrombose. Dtsch med Wschr 1984; 109: 1336-1339
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Breddin HK. Spätergebnisse nach Fibrinolysetherapie von Venenthrombosen. Internist 1984; 25: 102-107
    PubMedGoogle Scholar
  • 5 Albert FW, Schmidt U. Fibrinolyse thrombotischer Shuntverschlüsse bei Hämodialysepatienten.. In: Trübestein G, Etzel F. eds Fibrinolytic therapy p 573-577 Schattauer 1983;
    PubMedGoogle Scholar
  • 6 Mathey DG, Schofer J, Roewer N, Tilsner V, Becher H, Berkel H, Weidringer G. Intravenöser Urokinase-Bolus im Frühstadium des akuten Myokardinfarktes.. Verh dtsch Ges inn Med 90 1984; (in press)
    PubMedGoogle Scholar
  • 7 Tennant SN, Dixon J, Venable TC, Page Jr HL, Roach A, Kaiser AB, Frederiksen R, Tacogue L, Kaplan P, Babu NS, Anderson EE, Wooten E, Jennings III HS, Breinig J, Campbell WB. Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase. Circulation 1984; 69: 756-760
    CrossrefPubMedGoogle Scholar
  • 8 Yokoigawa K, Tanizawa K, Soda K. Purification of high molecular weight urokinase by reverse-immunoadsorption. Agric Biol Chem 1984; 48: 1587-1593
    PubMedGoogle Scholar
  • 9 Barlow GH, Francis CW, Marder VJ. On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin. Thromb Res 1981; 23: 541-547
    CrossrefPubMedGoogle Scholar
  • 10 Shibatani T, Kakimoto T, Chibata I. Purification of high molecular weight urokinase from human urine and comparative study of two active forms of urokinase. Thromb Haemostas 1983; 49: 91-95
    PubMedGoogle Scholar
  • 11 Huber K, Kirchheimer J, Binder BR. Rapid isolation of high molecular weight urokinase from native human urine. Thromb Haemostas 1982; 47: 197-202
    PubMedGoogle Scholar
  • 12 Proceedings of the 21st closed Japanese Urokinase Manufacturers Association. 1981
    PubMed
  • 13 Nobuhara M, Ashida Y, Ohnishi H. Contaminating substances in urokinase preparations. J Clin Pharmacy 1979; 4: 179-188
    PubMedGoogle Scholar
  • 14 Miyashita C, Köhler M, von Blohn G, Hellstern P, Wenzel E. Characterization and quality control of urokinase preparations. Blut 1984; 49: 118
    PubMedGoogle Scholar
  • 15 Nishida M, Nishimaki H, Miyake S, Suyama T, Morisue S. Physicochemical and biochemical properties of commercially available urokinase preparations. Thrombos Haemostas 1977; 38: 49 (Abstr.)
    PubMedGoogle Scholar
  • 16 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
    CrossrefPubMedGoogle Scholar
  • 17 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 18 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
    PubMedGoogle Scholar
  • 19 Greenwald SR, Chandler AB. Comparative study of thrombolysis by high and low molecular weight urokinase in an in vitro perfusion system. Thromb Res 1983; 31: 799-806
    CrossrefPubMedGoogle Scholar
  • 20 Gaffney PJ, Tydeman MS, Kirkwood TB, Aronson D, Murano G. International collaborative study on the assay of commercially available high and low molecular weight urokinases. Thromb Haemostas 1981; 45: 34-37
    PubMedGoogle Scholar
  • 21 Murano G, Aronson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma. Blood 1980; 55: 430-436
    PubMedGoogle Scholar
  • 22 Samama M, Castel M, Matsuo O, Hoylaerts M, Lijnen HR. Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin. Thromb Haemostas 1982; 47: 36-40
    PubMedGoogle Scholar